Robbins LLP Urges AARD Stockholders Who Lost Money Investing in Aardvark Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

Aardvark Therapeutics (AARD) faces a proposed securities class action alleging the company misled investors about the viability/efficacy and safety of lead drug candidate ARD-101. The complaint cites major stock drops tied to a voluntary Phase 3 HERO trial pause (down $7.02/share, -56.2% to $5.47 on Mar. 2, 2026) and a subsequent FDA full clinical hold (down $2.16/share, -32.1% to $4.57 on May 15, 2026). Investors who bought AARD in the Feb. 13, 2025–May 14, 2026 class period may be eligible to seek lead plaintiff status (deadline Oct. 13, 2026).

Analysis

For AARD, the lawsuit is mostly an incremental financing and governance overhang, not the primary value driver. In a single-asset, clinical-stage story, the equity is already priced as a binary option on regulatory recovery; once a full hold is in place, litigation mainly increases the probability of a punitive capital raise, stricter deal terms, or a longer gap before any resumption of clinical activity.

The key market mechanism is dilution rather than damages. If management needs to fund a remediation package, the company likely has to sell equity into a weak tape at a discount, potentially with warrants or structured protection, which can compress the stock further even if the legal case itself takes years to resolve. The real downside catalyst over the next 1-3 months is not the class action headline but any disclosure on cash runway, FDA correspondence, or protocol redesign costs.

Contrarianly, the market may be overpricing the lawsuit as a fresh negative when the science/regulatory setback already did the damage. If the balance sheet is still adequate and the company can show a credible path to lifting the hold, the stock may simply drift rather than collapse further. TGT looks like a non-factor here; there is no meaningful read-through to large-cap retail or broader litigation baskets from this event alone.

Key Decisions for Investors

• Avoid initiating a new long in AARD; treat it as a distressed event-driven biotech with equity value dependent on FDA remediation, not on the lawsuit itself.
• If borrow is available and liquidity supports it, short AARD only on strength/rally attempts, not into weakness; use the next 20-30% squeeze as entry, with the thesis that financing/dilution risk is the next catalyst.
• Prefer a pair trade: short AARD vs long XBI for 1-3 months, expressing idiosyncratic clinical/financing risk while neutralizing broad biotech beta; stop if FDA hold is lifted or a partner/non-dilutive funding package is announced.
• Set an alert on AARD cash runway disclosures and any 8-K/10-Q language around going concern, because a sub-12-month runway would materially increase probability of an equity raise and another leg lower.
• No action in TGT; the news has no economic transmission into mass-market retail fundamentals or targetable litigation exposure.